Dr. Frank R. Jones
President, Chief Scientific Officer
Dr. Jones, a founder of Etubics Corporation, is a seasoned bio-tech entrepreneur and scientist. As the founder of Etubics, Dr. Jones has served as the Company’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer since its inception. He is the Principle Investigator on many of the company’s National Institute of Health grants and contracts, which total over $20 million. He also designs and directs the clinical programs for the Company and led the “first in man” clinical trial using the Company’s Adenovirus vector platform. From 1981 to 1996, Dr. Jones served as Founding Chairman and Chief Executive Officer of the publicly traded medical device company, IMRÉ CORPORATION (now Cypress Biosciences), which focused on immunoadsorption treatments for various human diseases. From 1996 to 1998, Dr. Jones was Chairman and Chief Executive Officer of Scius Corporation, a private computer technology company which developed applications to manage and operate stirred tank manufacturing products. From 1998 to 2003 he consulted to the biotechnology industry and was the Managing Partner of Haidas Ranches, LLC a family-owned land development company. From 1983 until 1986, Dr. Jones was Director of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. He was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center (“MSKCC”) in New York City from 1980 to 1981 and was a Research Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983. Dr. Jones is member of the American Society of Clinical Oncology, American Association for Cancer Research and the Society for Immunotherapy of Cancer. He holds a Ph.D. degree from the University of Washington in Biological Structure/Cellular Immunology. He has 12 patents to his name and has published over 50 peer reviewed scientific papers. He has presented various business and scientific presentations on a national and international basis.
Ms. Carol R. Jones
Vice President of Administration
Ms. Jones was previously Vice President and Managing Partner of Haidas Ranches, LLC land development from 1996 to 2003. Ms. Jones has more than 20 years of administrative experience in various environments including seven years at the University of Washington working as a Budget Coordinator overseeing 16 grants and contracts with six figure annual budgets. She also has management experience from McDonnell Douglas Aircraft and Pacific Telephone and Telegraph in addition to having been involved in the administrative functions of two other startup companies including IMRÉ Corporation, of which was brought public. She graduated from Steven Henager College, Salt Lake City, Utah.
Ms. Elizabeth S. Gabitzsch
Vice President, Development
Ms. Gabitzsch is the Vice President, Research for the Etubics Corporation where she assumes the overall responsibility for the pre-clinical research and development of novel vaccines to treat cancers and infectious diseases. Under her leadership, the company has advanced from pre-clinical studies to clinical trials for a colorectal product. She has also brought the Company’s human E.C7 manufacturing cell line to the GMP Master Cell Bank stage and is a collaborator on several NIH funded grants exceeding millions of dollars in funding. Ms. Gabitzsch received academic training in microbiology, chemistry and immunology at Colorado State University. She is the leader in the peer reviewed publication of the studies that put forth the scientific basis for the Company’s technology. Her publications include advancing the development of vaccines against infectious agents such as HIV-1 and H1N1 and immunotherapeutic applications of the Etubics Platform against breast and colorectal cancers. Ms. Gabitzsch also presents the Company’s findings at domestic and international meetings. Before joining Etubics Corporation, she was previously at the Centers for Disease Control and Prevention (CDC) in the Division of Vector-borne and Infectious Diseases (DVBID). While at the CDC, Ms. Gabitzsch was a recipient of an Oak Ridge Institute of Science fellowship. Her areas of research focused on bacterial and viral vector-borne pathogens.